Senza5™ Platform Technology
Senza5™ Technology is a first-in-class, modular, platform technology that enhances the performance and safety of next generation T cell therapies.
Utilizing novel cell engineering technologies, Senza5™ T cells exploit the immuno-modulatory properties of an endogenous T cell signaling pathway to augment effector function and improve therapeutic outcomes.
Senza5™ T cells demonstrate SUPERIOR ANTI-TUMOR EFFICACY in both liquid and solid tumor animal models compared to contemporary cell therapies. Senza5™ engineered T cells also exhibit superior expansion and proliferative properties, reduced terminal differentiation, and enhanced effector phenotypes in both in-vitro and in-vivo experimental models.
Additionally, the inherent properties of Senza5™ T cells can improve patient outcomes by lowering dosing requirements, easing preconditioning regimens, reducing manufacturing failures, shortening vein-to-vein times, and by significantly enhancing the overall clinical utility of engineered T cell therapies.
Pioneering the Next Generation
of Cellular Therapies
Issues with targeting T cell neoplasms with CART immunotherapy
- Limited anti tumor effect
- CART cell fratricide
- Normal T cell toxicity
viTT-001 Next Generation Approach
- Enhanced tumor killing
- NO CART cell fratricide
- Reduced T cell toxicity
Address Unmet Clinical Need
viTToria's Clinical Pipeline is focused on novel indications with significant unmet clinical need and/or indications where current advanced therapies are either unavailable or cause extensive off target toxicity.
Enhance Efficacy
viTToria's Cellular Therapies leverage leading-edge gene editing and engineering technologies to generate T Cell therapies with superior effector and safety profiles.
Benefits include:
- Increased anti-tumor efficacy
- Improved antigen sensitivity
- Reduced terminal differentiation
- Increased expansion & persistence
Improve Safety
viTToria's Scientific Approach incorporates proprietary dual cell technologies, novel antigenic targeting, shorter manufacturing protocols, and lower dosing requirements to improve the safety profile of T cell therapies.
The approach aims to:
- Reduce or eliminate on-target, off-tumor toxicity
- Address non-malignant cell aplasia
- Reduce manufacturing failures
- Improve vein-to-vein time
